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Available online 10 July 2014Abstract Thyroid hormone is a critical regulator of cardiac growth and development, both in fetal life and postnatally. Here
we review the role of thyroid hormone in postnatal cardiac development, given recent insights into its role in stimulating a
burst of cardiomyocyte proliferation in the murine heart in preadolescence; a response required to meet the massive increase
in circulatory demand predicated by an almost quadrupling of body weight during a period of about 21 days from birth to
adolescence. Importantly, thyroid hormone metabolism is altered by chronic diseases, such as heart failure and ischemic heart
disease, as well as in very sick children requiring surgery for congenital heart diseases, which results in low T3 syndrome that
impairs cardiovascular function and is associated with a poor prognosis. Therapy with T3 or thyroid hormone analogs has been
shown to improve cardiac contractility; however, the mechanism is as yet unknown. Given the postnatal cardiomyocyte
mitogenic potential of T3, its ability to enhance cardiac function by promoting cardiomyocyte proliferation warrants further
consideration.
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Thyroid hormone (TH) is a critical regulator of many physio-
logical and developmental processes, following its activation
from the stable prohormone (L-thyroxine, T4) to the short-lived
active hormone, triiodothyronine (3,5,3′-triiodo-L-thyronine,
T3) (Fig. 1). T3 induces amphibian metamorphosis by stimulat-
ing the remodeling of specific tissues and organs (Tata, 1993).
In mammals, T3 is essential for development, with congenital
hypothyroidism resulting in growth retardation, deafness,
impaired neurogenesis, and congenital heart malformations
(Legrand, 1986; Olivieri et al., 2002). THs also have important
effects on oxygen consumption and metabolism. The actions of
THs are mediated by the products of two TH receptor (TR)
genes, the nuclear proteins, TRα and TRβ, which show
differential patterns of expression in development and in
adult tissues (Mai et al., 2004). Stimulation of these receptors
results in the direct transcriptional activation of a wide range
of genes (genomic effects). More recently, non-genomic
effects of TH initiated at the cell surface, in the cytoplasm or
in mitochondria have also been identified (Davis and Davis,
2002; Davis et al., 2011). Adding further complexity, TH
signaling is highly regulated by the expression of cell and
tissue-specific TH transporters that concentrate THs in target
cells, by the relative expression and distribution of TR isoforms,
by interaction of TRs with corepressors and coactivators,
by cross-talk with several other signaling pathways, and by
the sequence and location of the TH response element.
Furthermore, TH signaling is tightly regulated by the activation
and catabolism of THs by three selenoenzyme iodothyronineFigure 1 Deiodinase-mediated metabolism of thyroid hormone.
Deiodination of the outer, phenolic ring of T4 catalyzed by type 1 or
type 2 iodothyronine deiodinases (D1 or D2, respectively) converts
T4 to active T3. Both T4 and T3 are inactivated by deiodination of
the inner tyrosyl ring by Type 3 iodothyronine deiodinase (D3) to
yield reverse T3 or T2, respectively. D1 can also convert T4 to
reverse T3, which is further metabolized to T2 by D1 or D2.deiodinases: D1, D2 and D3—considerations that have been
comprehensively reviewed elsewhere (Zoeller et al., 2007;
Kress et al., 2009; Brent, 2012).
T3 has profound effects on the cardiovascular system
with chronic hyperthyroidism in adulthood resulting in a
physiological-type of cardiac hypertrophy, characterized by
a predominant increase in cardiomyocyte (CM) length rather
than width, and by enhanced expression of α-MHC, as well as
a marked reduction in systemic vascular resistance accom-
panied by increased cardiac contractility, systolic hyperten-
sion, and increased cardiac output. In contrast, prolonged
hypothyroidism results in diastolic hypertension, reduced
cardiac output and stroke volume, as well as cardiac
dilatation and even overt heart failure. The effects of T3
on the heart are due to the transcriptional regulation of a
number of contractile and calcium handling genes (Maillet et
al., 2013). These effects have been most widely studied with
respect to their role in postnatal heart development, and
under the premise that CMs exit the cell cycle and become
terminally differentiated soon after birth.
Here, after a brief consideration of TH biology, we
revisit the role of TH in postnatal heart development, given
recent evidence indicating that the proliferative compe-
tence of CMs may be retained until well after the neonatal
period, allowing murine CMs to undergo a proliferative
burst during preadolescence in response to a T3 surge
(Naqvi et al., 2014); that T3 can induce DNA synthesis in
terminally differentiated adult CMs (Ledda-Columbano et
al., 2006), and that remodeling post-myocardial infarction
in mice is associated with local hypothyroidism of spared
myocardium due to re-expression of D3, a
thyroid-inactivating enzyme normally expressed only in
the fetus (Janssen et al., 2013).TH biology
TH production and ontogeny of the hypothalamic–
pituitary–thyroid axis
TH is synthesized and secreted by the thyroid gland, a follicular
organ that synthesizes TH by iodination of tyrosine residues in
the glycoprotein, thyroglobulin. Thyroid stimulating hormone
(TSH) secreted by the anterior pituitary in response to
thyrotropin releasing hormone (TRH) elaborated by neurons
of the hypothalamic paraventricular nucleus activates TSH
receptors expressed on the basolateral membrane of thyroid
follicular cells. This results in adenylyl cyclase activation and
enhanced iodide uptake into the thyroid gland via the sodium/
iodide symporter, which in turn is used in the biosynthesis of
THs. Both T4 and T3 are synthesized and released from
the thyroid gland, are carried in the circulation bound to
specific proteins (thyroxine-binding globulin, transthyretin and
albumin), and exert a negative feedback on both the release of
pituitary TSH as well as on the activity of TRH on hypothalamic
neurons.
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Figure 2 Ontogeny of serum T3 and iodothyronine deiodinase
levels. A, Human and mouse serum T3 levels. (Data reproduced
from (Fisher and Klein, 1981; Hernandez et al., 2006;
Hadj-Sahraoui et al., 2000)) B, D1, D2 and D3 activities in
cerebrum and skin of female rats (Data +/− SE reproduced from
(Bates et al., 1999)).
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develops in the absence of maternal influences, since
neither the natural iodothyronines, T3, T4 and its inactive
metabolite, reverse T3 (rT3), nor TSH, can cross the
mammalian placenta. The fetal thyroid gland starts secret-
ing THs from midgestation in humans, and from3 to 5 days
before birth (embryonic days 17.5–18) in rats (Auso et al.,
2004; Ahmed et al., 2008; Morreale de Escobar et al., 2004),
with maturation of the hypothalamic–pituitary axis being
complete by birth in humans but delayed until approximate-
ly postnatal day 12–15 (P12–15) in rats and mice (Fisher and
Klein, 1981; Howdeshell, 2002). T3, T4 and TSH levels
increase markedly within a few hours of birth in humans to
levels 2 to 8-fold above those in cord blood (Fisher and Klein,
1981) (Fig. 2). These changes are driven, at least in part, by
postnatal cooling of the neonate (Fisher and Odell, 1969),
with the increase in T3 likely being compensatory to
enhance adaptive thermogenesis (Ribeiro et al., 2001). T3
and T4 levels also increase after birth in mice and rats
(Fig. 2), but more gradually with an initial peak at P5–6 and
then a more marked rise by P12–15 (Hadj-Sahraoui et al.,
2000) to levels 2.5- to 15-fold those observed at the end of
gestation (Howdeshell, 2002); the latter rise coincident with
maturation of the hypothalamo-hypophyseal portal system
and, thus, of the hypothalamic–pituitary–thyroid axis. Pre-
sumably, the delayed maturation of this axis in rodents
prevents a more rapid perinatal increase of T3, which in
humans occurs in response to postnatal cooling. Survival of
rodents despite the lack of a rapid increase in T3 levels and,
thus, thermogenesis, may perhaps be due to their ability to
rapidly activate autophagy, a response that allows the
neonatal animal to survive the profound starvation that occurs
during the period between birth and the onset of lactation
(Kuma et al., 2004). In this regard, it is of interest that fasting
suppresses the activity of TRH neurons (Zoeller et al., 2007).
Although target organ responses at the cellular level
are initiated by the binding of T3 to the TR, given the
complexities of TH signaling, target organ responses cannot
be predicted from circulating levels alone, but ultimately
depend on the level of TR occupancy. At normal adult serum
T3 levels, the contribution from serum T3 alone is approx-
imately 50% occupancy in most tissues. Thus, despite the
marked postnatal increases in T3 in the mouse, the initial
increase to the level seen at P5–6 would result in only a
small fraction of TRs being occupied, and even after the
later T3 increase at P12–15, there would at most be 50% TR
occupancy. TH action and concentration within cells are
relatively independent of circulating hormone levels be-
cause TH entry into cells occurs not only by diffusion, but
also via active and specific transcellular transport involving
members of the monocarboxylate transporter family (MCT8
and MCT10), organic anionic transport proteins (OATPs) and
L-type amino acid transporters (Zoeller et al., 2007; Gereben
et al., 2008), although only MCT8 and MCT10 appear to be
expressed in the heart (Danzi and Klein, 2014). In addition,
THs are subject to cellular metabolism by two 5′-deiodinases
(D1 and D2) that convert the prohormone T4 to T3 (Gereben
et al., 2008) (Fig. 1). Of these, D2 is critical as it resides in
the endoplasmic reticular (ER) membrane thereby allowing
ready access of cytosolically generated T3 to the nucleus
because of the proximity of the ER to the nuclear
compartment, and the long residence time (hours) of T3thus generated. In contrast, T3 generated by D1, a plasma
membrane-bound enzyme, rapidly (minutes) equilibrates
with plasma T3 and contributes little to local intracellular T3
production. A third deiodinase (D3) converts T4 and T3 to
the inactive iodothyronines, rT3 and T2, respectively.
Expression of these enzymes varies in different tissues and
throughout life. There is evidence that rodent CMs metab-
olize little or no T4 or T3 (Everts et al., 1996; Gereben et al.,
2008), consistent with low D1, D2 and D3 activities in the
healthy adult heart (Gereben et al., 2008). There are no
studies of deiodinase expression during cardiac develop-
ment, however, in general, D3 expression is high during fetal
585Thyroid hormone action in postnatal heart developmentlife, whereas expression of D1 and D2 increases after birth
(Fig. 2). Teleologically, D2 and D3 are thought to provide a
homeostatic mechanism for the reciprocal regulation of
thyroid activity in response to variations in environmental
iodine availability, as well as for controlling cellular TH
activity in a manner that is relatively independent of
circulating hormone levels (Gereben et al., 2008).TH receptors and signaling
The cellular actions of THmay be genomic (initiated within the
cell nucleus), non-genomic (at the plasma membrane, includ-
ing integrin αvβ3-mediated signaling or effects on membrane
ion channels/pumps, in the cytoplasm or at the level of the
mitochondria) or overlapping (Davis and Davis, 2002; Davis et
al., 2011). Postnatal cardiac development is a highly regulated
and programmed process. The role of TH in this process is
mainly via nuclear T3-activated TR-mediated transcriptional
regulation (Fig. 3). Classically, TH action includes the
transport of T3 into the target cell, including CMs, by TH
transporters and then the binding of T3 to nuclear TRs that in
turn hetero-dimerize with the retinoic acid receptor (RXR).
The TR–RXR complex thus formed then binds with high affinity
to T3 response elements (TREs; 10–15 bp located near
transcriptional start sites of T3-responsive genes) and recruits
coactivators, which increase histone acetylation. This leads to
an opening of chromatin structure that is permissive for target
gene transcription (Lazar, 1993; Brent, 1994; Harvey and
Williams, 2002). TH receptors found in the cytosol can also
bind T3 and activate the regulatory subunit (p85) of PI3 kinaseTRRXR
CoR
TRE
T3
plasma
membrane 
channels
signal
transduction
pathways
T3
cardiac
contractility
T
Figure 3 Thyroid hormone receptors and signaling in CMs. T3, triio
Binding of T3 to thyroid hormone receptors in the nucleus resul
high-affinity binding of the receptor complex to T3 response elem
effect). T3 can also directly modulate cell membrane ion channels, b
synthesis or mediate contractility (non-genomic effects).(PI3K), which in CMs has been shown to phosphorylate Akt and
mammalian target of rapamycin (mTOR) to increase protein
synthesis (Kenessey and Ojamaa, 2006). Although non-genomic
actions of T3 on contractility and membrane ion channels and
pumps have been documented, TH-mediated integrin signaling
has not been investigated in CMs (Davis and Davis, 2002; Davis
et al., 2011).
The effects of TH are mediated by the TRs, and both TRα
and TRβ are nuclear proteins. This is in contrast to steroid
hormone receptors, which directly regulate transcription,
but prior to activation are localized in the cytoplasm (Brent,
2012; Plateroti et al., 2001) (Fig. 3). Thus, TH must not only
gain access to the cell, but also to the nucleus, which,
as described above, requires coordination between circu-
lating TH levels, hormone uptake and conversion of the
prohormone T4 to T3 (Zoeller et al., 2007). Investigations in
various TR knock-out mice show that deletion of TRα1
results in hypothyroidism and significant cardiac effects
including bradycardia, decreased contractile function and
decreased contractile protein (α-myosin heavy chain) and
ion channel mRNA expression (HCN2 pacemaker channel and
the transient outward K+ channel, Ito) (Gloss et al., 2001;
Johansson et al., 1998; Wikstrom et al., 1998). Deletion of
TRβ results in hyperthyroidism and tachycardia; this is not
associated with contractile dysfunction or changes in Ito
mRNA expression, but expression of HCN2 and β-MHC mRNA
is increased (Gloss et al., 2001).
The TRα gene encodes a T3-binding splice variant, TRα1,
and two non-T3-binding splice variants (TRα2 and TRα3) (Cheng
et al., 2010). The TRβ gene encodes three T3-binding splice
variants, TRβ1-3, of which only TRβ1 and TRβ2 are expressedTRRXR
CoA T3
TRE
   transcription
e.g. SERCA-2
α-MHC
Na+/K+-ATPase
β-adrenergic receptor
IGF-1
TR PI3K/Akt mTOR
protein
synthesis
3
transporter
dothyronine, enters cells by diffusion or by specific transporters.
ts in heterodimerisation with the retinoic acid receptor and
ents to regulate transcription of T3-responsive genes (genomic
ind to cytoplasmic thyroid hormone receptors to increase protein
586 M. Li et al.in the heart (Schwartz et al., 1994; Jones et al., 2003).
Structurally, the DNA binding domains are similar for both TRα
and TRβ but they differ most in their amino termini, with TRα
having greater potency on TREs than TRβ (Hollenberg et al.,
1995). Cardiac TRα1 and TRα2 mRNA expression decreases
during postnatal development; in contrast to this change,
cardiac TRβ1 and TRβ2 mRNA expression increases (White et
al., 2001) such that TRα1 and TRβ1 each accounts for 40% of
T3-binding capacity in the adult and TRβ2 for 20% (Schwartz et
al., 1994). The impact of these changes is enhanced by the
opposite roles of the liganded (holoreceptor) and unliganded
(aporeceptor) states of the TRs. In the absence of T3, TH
aporeceptors recruit co-repressors and repress the transcrip-
tion of target genes (Fig. 3). When T3 levels increase after
birth, hormone binding results in the holoreceptor exchanging
co-repressors for co-activators. This activates transcription of
the same target genes that were previously repressed by the
aporeceptors (Hu and Lazar, 2000) (Fig. 3). Thus, in the mouse
fetus, TRα aporeceptors repress heart rate and TRβ expression,
as well as the expression of several genes encoding ion channels
involved in cardiac contractile activity. Immediately after
birth, the liganded TRα holoreceptor produces an increase in
heart rate via increased expression of some of the previously
repressed genes. Based on these considerations Mai et al.
(2004) propose that TRα acts as a molecular switch to control
heart function during early postnatal life.Postnatal cardiac development
In response to the rapid increase in body size, between birth
and puberty, the murine heart increases in size almost 4-fold,
with a commensurate increase in stroke volume (Naqvi et al.,
2014). How are these profound changes in cardiovascular
hemodynamics and morphology achieved?Cardiovascular hemodynamics
Postnatal developmental changes in cardiac contractility are
complex. The immature perinatal heart lacks T-tubules, has a
low density of diads and gap junctions, small CM size, poorly
developed sarcoplasmic reticulum and reduced sensitivity to
calcium ions (Vornanen, 1996). During the early postnatal
period cardiac contractile force increases commensurate with
increased expression and function of ion channels (Wetzel and
Klitzner, 1996); a response that continues until adulthood,
even after morphological development has already ceased
(Capasso et al., 1982; Leblanc et al., 1998). In addition to
enhanced ion channel expression and function, increases in
contractile performance are due to a number of developmen-
tal changes. These include: 1) maturation of excitation–
contraction coupling with increased expression of sarcolemmal
and reticular Ca2+ channels and transporters (Tanaka
and Shigenobu, 1989; Wibo et al., 1991); 2) changes in the
expression and ion-binding properties of contractile protein
isoforms (McAuliffe et al., 1990; Martin et al., 1991); and 3) the
development of autonomic innervation of the heart (Robinson,
1996). Early in the postnatal period, enhanced contractility is
mainly due to changes in Ca2+ transporter activity, contractile
protein phosphorylation, or both (Kameyama et al., 1986).
Long term, however, expression of these proteins also changes(Ogawa et al., 1992; Maki et al., 1996; Protas and Robinson,
1999).
TH contributes importantly to the maturational enhance-
ment of contractile function via a reciprocal effect on gene
transcription. Thus, TH increases the transcription of genes
encoding many cardiac proteins that enhance inotropy,
including the sarcoplasmic reticular Ca2+ATPase-2 (SERCA-2),
α-myosin heavy chain (α-MHC), the β1-adrenergic receptor,
Na+/K+-ATPase, cardiac troponin I (CTNI), and voltage-gated
potassium channels (v1.5, Kv4.2, Kv4.3) (Klein and Danzi,
2007; Maillet et al., 2013). However, TH also inhibits the
expression of genes encoding proteins that in some cases
suppress contractile function, such as β-MHC, phospholamban,
as well as suppressing the expression of the Na+–Ca2+
exchanger (NCX), TRα1, and type V and VI adenylyl cyclases
(ACs) (Arsanjani et al., 2011). Not surprisingly, therefore, T3
administration not only stimulates the expression of α-MHC,
the high ATPase activity MHC isoform, but also decreases the
expression of β-MHC (Morkin, 1993; Lompre et al., 1984; Izumo
and Mahdavi, 1988). Conversely, hypothyroidism inhibits
α-MHC expression and stimulates β-MHC expression; an effect
mediated by miR-208, a cardiac-specific microRNA (van Rooij
et al., 2007).
In addition to profound changes in cardiac contractility,
postnatal development is associated with an increase in
blood volume that is driven by the rapid body growth that
occurs during this period, as well as by increases in blood
pressure, stroke volume and cardiac output (D'Souza et al.,
1995; Jurko, 2004). TH is an important regulator of these
hemodynamic alterations (Danzi and Klein, 2012; Biondi et
al., 2002). Supporting this are the findings that hyperthy-
roidism is associated with an increase in blood volume,
venous volume return, cardiac output, contractility, heart
rate and pulse pressure, and a decrease in systemic vascular
resistance (Klein and Ojamaa, 2001). And conversely,
hypothyroidism is associated with a decrease in cardiac
output, a narrow pulse pressure, and an increase in systemic
vascular resistance (Bengel et al., 2003; Danzi and Klein,
2003; Biondi et al., 2002; Kiss et al., 1994). The T3-induced
decline in systemic vascular resistance stimulates renin
release and sodium reabsorption, resulting in blood volume
expansion and an increase in venous return (Resnick and
Laragh, 1982). Erythropoietin stimulation also contributes to
the rise in blood volume. Heart rate and cardiac output
increase significantly (by up to 300%) in the hyperthyroid
state versus euthyroid controls. The net effect of these
hemodynamic changes is a rise in systolic blood pressure and
a widening of pulse pressure (Prisant et al., 2006). The
increase in cardiovascular hemodynamics allows for in-
creased blood flow leading to enhanced perfusion to provide
for the substrate and oxygen demands of peripheral tissues
(Biondi et al., 2002).Cardiac morphology
Preload is the hemodynamic force exerted on the ventricular
wall during filling and, thus, is directly responsible for
ventricular end-diastolic wall stress or tension sensu strictu.
It contributes greatly to the determination of ventricular
end-diastolic volume and modulates myocardial performance
significantly. That is, it governs the extent and velocity of wall
P10 P14 P15
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hypertrophy
LV-restricted
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Left ventricle
pro-proliferative gene expression
mono- and binuclear CM volume
mononuclear CM numbers
binuclear CM numbers
No cardiac dysfunction
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Figure 4 A model for maturational heart growth during early preadolescence. Maturational heart growth during early
preadolescence (P10 to P14) is characterized by eccentric hypertrophy where the increase in LV chamber dimension is not matched
by a corresponding increase in LV wall thickness (h). This leads to a decrease in LV h/Ri ratio (Ri is the internal LV chamber radius),
which is expected to increase LV wall stress due to considerations of the Law of Laplace. The change in heart shape is produced by a
T3 surge soon after P10, which results in a prominent increase in CM length with minimal change in CM width, and an increase in
α-MHC by P14. This is followed by proliferation of mono- and bi−nuclear CMs between P14 and P15, which increased CM numbers by
about 40%, thereby establishing the final CM population number during preadolescence.
Adapted from Naqvi et al. (2014).
587Thyroid hormone action in postnatal heart developmentshortening. Thus, preload plays a major role in regulating
stroke volume via the Frank–Starling mechanism. Recently, we
found in the mouse that a growth spurt that almost quadruples
body weight (and hence circulatory volume) between P10 and
P35 is associated with a commensurate 3.5-fold increase in
stroke volume (Naqvi et al., 2014). This profound maturational
adaptation leads to left ventricular (LV) chamber remodeling,
which is characterized by an 86% increase in LV end diastolic
dimension (LVEDD) that results in a 4.6-fold increase in LV
volume at diastole without a significant change in LV free wall
thickness at diastole (FWd or h) (Fig. 4). These changes in
ventricular morphology produced a 52% decrease in the LV h/Ri
ratio (where Ri is the internal LV chamber radius), consistent
with eccentric hypertrophy, and maintained LV weight-
to-stroke volume ratio (1.76:1 at P10 versus 1.78:1 at P35).
Also, between P10 and P35, LVEDD length-to-diameter ratio
decreased by 40% indicating an increase in LV sphericity. At the
cellular level, CM length increased 1.7-fold between P10 and
P35, with little change in CM width. Detailed analysis of the
morphological changes in heart size during this postnatal
period from P10 to P35, revealed three distinct growth phases:
the first and third between P10 and P14, and P18 and P35,
respectively, involve a physiological-type of hypertrophic
growth with no change in the number of CMs, whereas an
intervening period between P11 and P18 involves heart growth
due to CMhyperplasia that results from proliferation of existing
CMs, rather than to thematuration of cardiac stem cells (Fig. 4)
(Naqvi et al., 2014). Importantly, the adaptive LV remodeling
of postnatal maturational growth represents a distinct form of
physiological hypertrophy that differs from the pathological
hypertrophy associated with the LV volume-overload of
mitral regurgitation, where cardiac performance continuously
degrades over time (Schiros et al., 2013), and from the
physiological hypertrophy associated with endurance exercise,
where the increases in LV chamber volume are accommodated
by elliptical remodeling of the heart (Schiros et al., 2013) thatlimits the increase in LVEDD and, thus, in LV end-diastolic wall
stress.
Involvement of TH in this adaptive preadolescent growth
of the heart was suggested by marked CM elongation as
well as by an increase in the ratio of α- to β-MHC mRNA
expression (Fig. 4) (Naqvi et al., 2014), findings consistent
with a T3-mediated effect, since neither physiological nor
pathological cardiac hypertrophy cause large changes in the
α- to β-MHC mRNA ratio, but T3 excess does (Haddad et al.,
2008). This is important as increased expression of α-MHC,
the fast ATPase activity MHC isoform, correlates directly
with overall cardiac performance (Krenz and Robbins, 2004).
Further, we showed that a surge in circulating T3 levels
(5.6-fold increase) precedes the period of CM hyperplasia,
and that blockade of T3 biosynthesis with the goitrogen,
propylthiouracil (PTU), prevents the increase in α- to β-MHC
ratio and in heart weight, as well as the increase in the
number of CMs observed during the period of maturational
growth between P10 and P18. Given that the surge in
circulating T3 levels precedes the CM hyperplastic response
by several days, it is unclear if T3-induced CM proliferation is
due to a direct or indirect effect. Direct involvement of T3 in
CM hyperplasia was suggested by a T3-stimulated increase in
DNA synthesis in vitro (Naqvi et al., 2014). In support of an
indirect effect, we showed that PTU treatment inhibits a
developmental increase in cardiac IGF-1 protein and mRNA
expression, and cardiac IGF-1 receptor and Akt phosphory-
lation at P15. The associated abrupt nuclear localization of
Akt in CMs at P15 is important because nuclear overexpres-
sion of Akt causes CM proliferation (Rota et al., 2005). These
findings are supported by an earlier report that showed a
pharmacologic effect of T3 administration on cardiac IGF-1
mRNA expression (Kupfer and Rubin, 1992). The effect of T3
on CM proliferation could possibly also involve a morpholog-
ical change in CM dimensions. T3 prominently increases
CM length in cell culture (Pantos et al., 2007). In some
588 M. Li et al.eukaryotic cells, cell division is triggered by progressive
cellular elongation that disinhibits a kinase cascade involved
in cell cycle reentry (Moseley and Nurse, 2010). Others have
found that in fetal rat and sheep, hemodynamic load, which is
expected to increase wall stress, is required for a TH-induced
increase in ventricular mass (Torres and Tucker, 1993; Segar
et al., 2013). We found that postnatal developmental
changes in heart morphology favor an uncompensated
increase in LV wall stress. Wall stress is a major impetus
for cell division in fetal and neonatal CMs in vivo (Saiki et
al., 1997; Sedmera et al., 2003). Mathematical modeling
suggests that this stress is greater in subendocardium than
in subepicardium (Mirsky, 1973). This could, in part explain
why we found that CM hyperplasia in P15 hearts is more
evident in the longitudinal subendocardial than in the
circumferential subepicardial cardiac myofibers. All of
these considerations suggest that the CM hyperplastic
response during maturational heart growth may involve
interplay between endocrine, paracrine, morphologic and
hemodynamic factors.
Our contention that T3 triggers the postnatal CM
hyperplastic response during maturational heart growth is
not always, at first glance, consistent with earlier reports.
For example, Chattergoon et al. (2012) evaluated the
effects on fetal CM maturation of T3 given to sheep by
infusion on gestational days 125–130 (term ~145 days).
These studies suggested that T3 augments CM maturation, as
evidenced by increases in cell width, binucleation and
expression of the cell cycle inhibitor, p21, as well as by
reductions in cyclin D1 and in cell proliferation. Increased
expression of phospho-mTOR, ANP and SERCA2a also sug-
gested that T3 promoted CM hypertrophy. However, a
hallmark of T3-induced hypertrophy is CM enlargement due
mainly to cell elongation, not to an increase in width; the
latter being observed with pathological hypertrophy. Simi-
larly, SERCA2a expression falls with pathological hypertro-
phy. Thus, the findings of Chattergoon et al., suggest that
the CM responses observed are complex with elements of
both T3-induced and pathological hypertrophy. Given that
T3 administration was ‘ectopic’ in their study, that is, it was
given at a time when circulating T3 levels are normally very
low, the relevance of these findings for physiological
postnatal CM maturation remains unclear. In addition,
given that the hemodynamic load on the heart is low during
gestation, it is perhaps not surprising that Chattergoon et al.
did not observe a hyperplastic effect of T3 on fetal CMs. Of
interest in this regard, Yang et al. (2014) reported that T3
drives maturation of CMs derived from human induced
pluripotent stem cells (hiPSC-CM); again a situation where
T3 is acting on CMs in the absence of a hemodynamic load.
Thus, much work is still required to understand the context
under which T3 functions as a mitogen in the preadolescent
heart.
TH and the heart: potential
therapeutic implications
TH replacement has been trialed in the operative setting in
an attempt to minimize morbidity and to increase survival of
children undergoing complex congenital heart disease
surgery (Chowdhury et al., 2001). T3 therapy in theseextremely sick patients is aimed at improving cardiac
function and optimizing postoperative hemodynamics that
may result from observed changes in TH metabolism, which
decreases circulating T3 levels, as well as reducing
TR-expression (particularly TRα) (Dillmann, 2010). TH levels
also fall acutely in humans following myocardial infarction
and replacement therapy with either T3 or the synthetic TH
analog, 3,5-diiodothyroproprionic acid (DITPA), which exerts
a positive inotropic effect without the potential adverse
effects of iatrogenic hyperthyroidism (e.g., tachyarrhyth-
mias, weight loss, anxiety), has been used to limit
post-infarct patholological remodeling in preclinical studies
(Zheng et al., 2004; Spooner et al., 1999; Mahaffey et al.,
1995), as well as in clinical trials of patients with heart
failure (Morkin et al., 2002; Goldman et al., 2009). Again in
these studies, the rationale for using TH or analogs is largely
to enhance cardiac contractility of the uninjured or failing
myocardium in situations where TH metabolism is impaired
and T3 levels are low (Gerdes and Iervasi, 2010). Where TH
metabolism is unaltered, T3 would have to be given with
caution as it could potentially deleteriously increase cardiac
work and myocardial O2 consumption, although DITPA, with
its lack of adverse cardiac effects, should be tolerated.
Although adult CMs have very limited proliferative
capacity, it has been suggested that a small population of
these cells in regions adjacent to a myocardial infarct,
retain the ability to divide (Kajstura et al., 1998; Beltrami
et al., 2001). Thus, enhancing their proliferation may
augment repair in response to myocardial injury. To this
end, Ledda-Columbano et al. (2006) treated rats with T3 for
up to 7 days. This resulted in CM cell cycle reentry, as
demonstrated by increased expression of cyclin D1, as well
as by increased CM cyclin A (a specific S phase marker) and
proliferating cell nuclear antigen (PCNA) labeling; in-
creased bromodeoxyuridine incorporation into CM DNA,
and increased labeling by the mitotic marker,
phospho-histone-3. These findings are consistent with the
studies of Soonpaa et al. (1997), who showed that
CM-targeted cyclin D1 overexpression from birth promotes
CM DNA synthesis in mice and results in infarct regression.
Tane et al. (2014) have recently shown, however, that
induction of cyclin D1 expression in adult murine CMs results
in cell cycle re-entry of N40% of CMs, but that the cell cycle
is arrested in mitosis. Thus, cell cycle reentry is not
necessarily synonymous with cell proliferation, so it is
unfortunate that Ledda-Columbano et al. (2006) did not
quantitate CM numbers in T3-treated animals.
Apart from the direct effects of the loss of pump function
that follows the massive loss of CMs and subsequent necrosis
and fibrosis associated with myocardial infarction, impaired
contractility also results in the functional and structural
remodeling of spared myocardium. In preclinical models of
infarction, DITPA has been shown to attenuate this patho-
logical post-infarct remodeling, although by a mechanism
that may involve induction of angiogenesis and arteriolar
growth, as well as by limiting the inflammatory response
(Zheng et al., 2004; Abohashem-Aly et al., 2011). Of note in
this regard, Janssen et al. (2013) have recently reported
that post-infarct remodeling is associated with a marked
(6-fold) increase in the expression of D3 in spared myocar-
dium. It would be of interest, therefore, to determine if
therapy with T3 or DITPA, might also improve remodeling by
589Thyroid hormone action in postnatal heart developmentan independent mechanism, involving rescue of the relative
hypothyroid myocardium resulting from increased D3 ex-
pression and, thus, augmentation of CM proliferation.
Summary and future perspective
During postnatal cardiac development, TH mediates direct
transcriptional activation of genes involved in cardiac
contractility, regulates hemodynamic changes such as stroke
volume, blood volume, heart rate and blood pressure that
are associated with the rapid increase in body size during
this period, and it initiates a brief burst of subendocardial
CM proliferation in preadolescence that involves activation
of the IGF-1/IGF-1R/Akt pathway. Although further studies
are required to delineate the regulatory mechanisms that
govern the complex spatial and temporal actions of TH in the
cardiovascular system, insights gained from such studies will
prove invaluable in the development of effective myocardial
regenerative therapies for the treatment of inherited and
acquired heart diseases.
Acknowledgments
We gratefully acknowledge support from NIH (HL079040; to AH);
John and Mary Brock Translational Research Fund grant (to AH);
Regenerative Engineering and Medicine (REM) center at Emory and
Georgia Tech grant (to AH, NN); Emory and Children's Center for
Cardiovascular Biology pilot grant (to AH, NN); American Heart
Association Scientist Development grant (13SD16460006; to NN);
National Health and Medical Research Council of Australia grants
(573732 & 1012190; to RMG, SEI, ML); Heart Foundation of Australia
grant (G10S 5148; to RMG, ML, SEI); RT Hall Estate grant (to RMG,
ML, SEI); and an Australian Research Council Stem Cells Australia,
Special Initiative in Stem Cell Science grant (SR110001002; to
RMG).
References
Abohashem-Aly, A.A., Meng, X., Li, J., Sadaria, M.R., L Ao,
Wennergren, J., Fullerton, D.A., Raeburn, C.D., 2011. DITPA, a
thyroid hormone analog, reduces infarct size and attenuates the
inflammatory response following myocardial ischemia. J. Surg.
Res. 171, 379–385.
Ahmed, O.M., El-Gareib, A.W., El-Bakry, A.M., Abd El-Tawab, S.M.,
Ahmed, R.G., 2008. Thyroid hormones states and brain develop-
ment interactions. Int. J. Dev. Neurosci. 26, 147–209.
Arsanjani, R., Mccarren, M., Bahl, J.J., Goldman, S., 2011.
Translational potential of thyroid hormone and its analogs. J.
Mol. Cell. Cardiol. 51, 506–511.
Auso, E., Lavado-Autric, R., Cuevas, E., Del Rey, F.E., Morreale De
Escobar, G., Berbel, P., 2004. A moderate and transient
deficiency of maternal thyroid function at the beginning of fetal
neocorticogenesis alters neuronal migration. Endocrinology 145,
4037–4047.
Bates, J.M., St Germain, D.L., Galton, V.A., 1999. Expression
profiles of the three iodothyronine deiodinases, D1, D2, and
D3, in the developing rat. Endocrinology 140, 844–851.
Beltrami, A.P., Urbanek, K., Kajstura, J., Yan, S.M., Finato, N.,
Bussani, R., Nadal-Ginard, B., Silvestri, F., Leri, A., Beltrami, C.A.,
Anversa, P., 2001. Evidence that human cardiac myocytes divide
after myocardial infarction. N. Engl. J. Med. 344, 1750–1757.
Bengel, F.M., Lehnert, J., Ibrahim, T., Klein, C., Bulow, H.P.,
Nekolla, S.G., Schwaiger, M., 2003. Cardiac oxidative metabolism,
function, and metabolic performance in mild hyperthyroidism: anoninvasive study using positron emission tomography and
magnetic resonance imaging. Thyroid 13, 471–477.
Biondi, B., Palmieri, E.A., Lombardi, G., Fazio, S., 2002. Effects of
thyroid hormone on cardiac function: the relative importance of
heart rate, loading conditions, and myocardial contractility in
the regulation of cardiac performance in human hyperthyroid-
ism. J. Clin. Endocrinol. Metab. 87, 968–974.
Brent, G.A., 1994. The molecular basis of thyroid hormone action.
N. Engl. J. Med. 331, 847–853.
Brent, G.A., 2012. Mechanisms of thyroid hormone action. J. Clin.
Invest. 122, 9035–9043.
Capasso, J.M., Remily, R.M., Sonnenblick, E.H., 1982. Alterations in
mechanical properties of rat papillary muscle during maturation.
Am. J. Physiol. 242, H359–H364.
Chattergoon, N.N., Giraud, G.D., Louey, S., Stork, P., Fowden, A.L.,
Thornburg, K.L., 2012. Thyroid hormone drives fetal cardiomyo-
cyte maturation. FASEB J. 26, 397–408.
Cheng, S.Y., Leonard, J.L., Davis, P.J., 2010. Molecular aspects of
thyroid hormone actions. Endocr. Rev. 31, 139–170.
Chowdhury, D., Ojamaa, K., Parnell, V.A., Mcmahon, C., Sison, C.
P., Klein, I., 2001. A prospective randomized clinical study of
thyroid hormone treatment after operations for complex
congenital heart disease. J. Thorac. Cardiovasc. Surg. 122,
1023–1025.
Danzi, S., Klein, I., 2003. Thyroid hormone and blood pressure
regulation. Curr. Hypertens. Rep. 5, 513–520.
Danzi, S., Klein, I., 2012. Thyroid hormone and the cardiovascular
system. Med. Clin. North Am. 96, 257–268.
Danzi, S., Klein, I., 2014. Thyroid disease and the cardiovascular
system. Endocrinol. Metab. Clin. North Am. 43, 517–528.
Davis, P.J., Davis, F.B., 2002. Nongenomic actions of thyroid
hormone on the heart. Thyroid 12, 459–466.
Davis, P.J., Lin, H.Y., Mousa, S.A., Luidens, M.K., Hercbergs, A.A.,
Wehling, M., Davis, F.B., 2011. Overlapping nongenomic and
genomic actions of thyroid hormone and steroids. Steroids 76,
829–833.
Dillmann, W., 2010. Cardiac hypertrophy and thyroid hormone
signaling. Heart Fail. Rev. 15, 125–132.
D'Souza, S.W., Janakova, H., Minors, D., Suri, R., Waterhouse, J.,
Appleton, G., Ramesh, C., Sims, D.G., Chiswick, M.L., 1995.
Blood pressure, heart rate, and skin temperature in preterm
infants: associations with periventricular haemorrhage. Arch.
Dis. Child Fetal Neonatal Ed. 72, F162–F167.
Everts, M.E., Verhoeven, F.A., Bezstarosti, K., Moerings, E.P.,
Hennemann, G., Visser, T.J., Lamers, J.M., 1996. Uptake of
thyroid hormones in neonatal rat cardiac myocytes. Endocrinology
137, 4235–4242.
Fisher, D.A., Klein, A.H., 1981. Thyroid development and disorders of
thyroid function in the newborn. N. Engl. J. Med. 304, 702–712.
Fisher, D.A., Odell, W.D., 1969. Acute release of thyrotropin in the
newborn. J. Clin. Invest. 48, 1670–1677.
Gerdes, A.M., Iervasi, G., 2010. Thyroid replacement therapy and
heart failure. Circulation 122, 385–393.
Gereben, B., Zavacki, A.M., Ribich, S., Kim, B.W., Huang, S.A.,
Simonides, W.S., Zeöld, A., Bianco, A., 2008. Cellular and
molecular basis of deiodinase-regulated thyroid hormone signal-
ing. Endocr. Rev. 29, 898–938.
Gloss, B., Trost, S., Bluhm, W., Swanson, E., Clark, R., Winkfein, R.,
Janzen, K., Giles, W., Chassande, O., Samarut, J., Dillmann, W.,
2001. Cardiac ion channel expression and contractile function in
mice with deletion of thyroid hormone receptor alpha or beta.
Endocrinology 142, 544–550.
Goldman, S., Mccarren, M., Morkin, E., Ladenson, P.W., Edson, R.,
Warren, S., Ohm, J., Thai, H., Churby, L., Barnhill, J., O'Brien, T.,
Anand, I., Warner, A., Hattler, B., Dunlap, M., Erikson, J., Shih, M.
C., Lavori, P., 2009. DITPA (3,5-diiodothyropropionic acid), a
thyroid hormone analog to treat heart failure: phase II trial
veterans affairs cooperative study. Circulation 119, 3093–3100.
590 M. Li et al.Haddad, F., Qin, A.X., Bodell, P.W., Jiang, W., Giger, J.M., Baldwin,
K.M., 2008. Intergenic transcription and developmental regula-
tion of cardiac myosin heavy chain genes. Am. J. Physiol. Heart
Circ. Physiol. 294, H29–H40.
Hadj-Sahraoui, N., Seugnet, I., Ghorbel, M.T., Demeneix, B., 2000.
Hypothyroidism prolongs mitotic activity in the post-natal mouse
brain. Neurosci. Lett. 280, 79–82.
Harvey, C.B., Williams, G.R., 2002. Mechanism of thyroid hormone
action. Thyroid 12, 441–446.
Hernandez, A., Martinez, M.E., Fiering, S., Galton, V.A., St Germain,
D., 2006. Type 3 deiodinase is critical for the maturation and
function of the thyroid axis. J. Clin. Invest. 116, 476–484.
Hollenberg, A.N., Monden, T., Wondisford, F.E., 1995. Ligand-
independent and -dependent functions of thyroid hormone
receptor isoforms depend upon their distinct amino termini. J.
Biol. Chem. 270, 14274–14280.
Howdeshell, K.L., 2002. A model of the development of the brain as
a construct of the thyroid system. Environ. Health Perspect. 110,
337–348.
Hu, X., Lazar, M.A., 2000. Transcriptional repression by nuclear
hormone receptors. Trends Endocrinol. Metab. 11, 6–10.
Izumo, S., Mahdavi, V., 1988. Thyroid hormone receptor alpha
isoforms generated by alternative splicing differentially activate
myosin HC gene transcription. Nature 334, 539–542.
Janssen, R., Zuidwijk, M., Muller, A., Mulders, J., Oudejans, C.B.,
Simonides, W.S., 2013. Cardiac expression of deiodinase type 3
(Dio3) following myocardial infarction is associated with the
induction of a pluripotency microRNA signature from the Dlk1-
Dio3 genomic region. Endocrinology 154, 1973–1978.
Johansson, C., Vennstrom, B., Thoren, P., 1998. Evidence that
decreased heart rate in thyroid hormone receptor-alpha1-
deficient mice is an intrinsic defect. Am. J. Physiol. 275,
R640–R646.
Jones, I., Srinivas, M., Ng, L., Forrest, D., 2003. The thyroid
hormone receptor beta gene: structure and functions in the
brain and sensory systems. Thyroid 13, 1057–1068.
Jurko, A.J., 2004. Echocardiographic evaluation of left ventricle
postnatal growth in newborns and infants. Bratisl. Lek. Listy 105,
78–85.
Kajstura, J., Leri, A., Finato, N., Di Loreto, C., Beltrami, C.A., Anversa,
P., 1998. Myocyte proliferation in end-stage cardiac failure in
humans. Proc. Natl. Acad. Sci. U. S. A. 95, 8801–8805.
Kameyama, M., Hescheler, J., Hofmann, F., Trautwein, W., 1986.
Modulation of Ca current during the phosphorylation cycle in
the guinea pig heart. Pflugers Arch. 407, 123–128.
Kenessey, A., Ojamaa, K., 2006. Thyroid hormone stimulates protein
synthesis in the cardiomyocyte by activating the Akt-mTOR and
p70S6K pathways. J. Biol. Chem. 281, 20666–20672.
Kiss, E., Jakab, G., Kranias, E.G., Edes, I., 1994. Thyroid hormone-
induced alterations in phospholamban protein expression.
Regulatory effects on sarcoplasmic reticulum Ca2+ transport
and myocardial relaxation. Circ. Res. 75, 245–251.
Klein, I., Danzi, S., 2007. Thyroid disease and the heart. Circulation
116, 1725–1735.
Klein, I., Ojamaa, K., 2001. Thyroid hormone and the cardiovascular
system. N. Engl. J. Med. 344, 501–509.
Krenz, M., Robbins, J., 2004. Impact of beta-myosin heavy chain
expression on cardiac function during stress. J. Am. Coll. Cardiol.
44, 2390–2397.
Kress, E., Samarut, J., Plateroti, M., 2009. Thyroid hormones and
the control of cell proliferation or cell differentiation: paradox
or duality? Mol. Cell. Endocrinol. 313, 36–49.
Kuma, A., Hatano, M., Matsui, M., Yamamoto, A., Nakaya, H.,
Yoshimori, T., Ohsumi, Y., Tokuhisa, T., Mizushima, N., 2004.
The role of autophagy during the early neonatal starvation
period. Nature 432, 1032–1036.
Kupfer, J.M., Rubin, S.A., 1992. Differential regulation of insulin-
like growth factor I by growth hormone and thyroid hormone inthe heart of juvenile hypophysectomized rats. J. Mol. Cell.
Cardiol. 24, 631–639.
Lazar, M.A., 1993. Thyroid hormone receptors: multiple forms,
multiple possibilities. Endocr. Rev. 14, 184–193.
Leblanc, N., Chartier, D., Gosselin, H., Rouleau, J.L., 1998. Age
and gender differences in excitation–contraction coupling of
the rat ventricle. J. Physiol. 511 (Pt 2), 533–548.
Ledda-Columbano, G.M., Molotzu, F., Pibiri, M., Cossu, C., Perra, A.,
Columbano, A., 2006. Thyroid hormone induces cyclin D1 nuclear
translocation and DNA synthesis in adult rat cardiomyocytes.
FASEB J. 20, 87–94.
Legrand, J., 1986. Thyroid hormone effects on growth and
development. In: Henneman, G. (Ed.), Thyroid Hormone Metab-
olism. Marcel Dekker, Rotterdam, The Netherlands.
Lompre, A.M., Nadal-Ginard, B., Mahdavi, V., 1984. Expression of
the cardiac ventricular alpha- and beta-myosin heavy chain
genes is developmentally and hormonally regulated. J. Biol.
Chem. 259, 6437–6446.
Mahaffey, K.W., Raya, T.E., Pennock, G.D., Morkin, E., Goldman, S.,
1995. Left ventricular performance and remodeling in rabbits
after myocardial infarction. Effects of a thyroid hormone
analogue. Circulation 91, 794–801.
Mai, W., Janier, M.F., Allioli, N., Quignodon, L., Chuzel, T., Flamant,
F., Samarut, J., 2004. Thyroid hormone receptor alpha is a
molecular switch of cardiac function between fetal and postnatal
life. Proc. Natl. Acad. Sci. U. S. A. 101, 10332–10337.
Maillet, M., Van Berlo, J.H., Molkentin, J.D., 2013. Molecular
basis of physiological heart growth: fundamental concepts
and new players. Nat. Rev. Mol. Cell Biol. 14, 38–48.
Maki, T., Gruver, E.J., Davidoff, A.J., Izzo, N., Toupin, D., Colucci,
W., Marks, A.R., Marsh, J.D., 1996. Regulation of calcium
channel expression in neonatal myocytes by catecholamines.
J. Clin. Invest. 97, 656–663.
Martin, A.F., Ball, K., Gao, L.Z., Kumar, P., Solaro, R.J., 1991.
Identification and functional significance of troponin I isoforms
in neonatal rat heart myofibrils. Circ. Res. 69, 1244–1252.
McAuliffe, J.J., Gao, L.Z., Solaro, R.J., 1990. Changes in myofibril-
lar activation and troponin C Ca2+ binding associated with
troponin T isoform switching in developing rabbit heart. Circ.
Res. 66, 1204–1216.
Mirsky, I., 1973. Ventricular and arterial wall stresses based on large
deformation analyses. Biophys. J. 13, 1141–1159.
Morkin, E., 1993. Regulation of myosin heavy chain genes in the
heart. Circulation 87, 1451–1460.
Morkin, E., Pennock, G.D., Spooner, P.H., Bahl, J.J., Goldman, S.,
2002. Clinical and experimental studies on the use of 3,5-
diiodothyropropionic acid, a thyroid hormone analogue, in heart
failure. Thyroid 12, 527–533.
Morreale De Escobar, G., Obregon, M.J., Escobar Del Rey, F., 2004.
Role of thyroid hormone during early brain development. Eur. J.
Endocrinol. 151 (Suppl. 3), U25–U37.
Moseley, J.B., Nurse, P., 2010. Cell division intersects with cell
geometry. Cell 142, 184–188.
Naqvi, N., Li, M., Calvert, J.W., Tejada, T., Lambert, J.P., Wu, J.,
Kesteven, S.H., Holman, S.R., Matsuda, T., Lovelock, J.D.,
Howard, W.W., Iismaa, S.E., Chan, A.Y., Crawford, B.H.,
Wagner, M.B., Martin, D.I., Lefer, D.J., Graham, R.M., Husain,
A., 2014. A proliferative burst during preadolescence establishes
the final cardiomyocyte number. Cell 157, 795–807.
Ogawa, S., Barnett, J.V., Sen, L., Galper, J.B., Smith, T.W., Marsh,
J.D., 1992. Direct contact between sympathetic neurons and rat
cardiac myocytes in vitro increases expression of functional
calcium channels. J. Clin. Invest. 89, 1085–1093.
Olivieri, A., Stazi, M.A., Mastroiacovo, P., Fazzini, C., Medda, E.,
Spagnolo, A., De Angelis, S., Grandolfo, M.E., Taruscio, D.,
Cordeddu, V., Sorcini, M., Study Group for Congenital
Hypothyroidism, 2002. A population-based study on the fre-
quency of additional congenital malformations in infants with
591Thyroid hormone action in postnatal heart developmentcongenital hypothyroidism: data from the Italian Registry for
Congenital Hypothyroidism (1991–1998). J. Clin. Endocrinol.
Metab. 87, 557–562.
Pantos, C., Xinaris, C., Mourouzis, I., Malliopoulou, V., Kardami, E.,
Cokkinos, D.V., 2007. Thyroid hormone changes cardiomyocyte
shape and geometry via ERK signaling pathway: potential
therapeutic implications in reversing cardiac remodeling? Mol.
Cell. Biochem. 297, 65–72.
Plateroti, M., Gauthier, K., Domon-Dell, C., Freund, J.N., Samarut,
J., Chassande, O., 2001. Functional interference between
thyroid hormone receptor alpha (TRalpha) and natural truncated
TRDeltaalpha isoforms in the control of intestine development.
Mol. Cell. Biol. 21, 4761–4772.
Prisant, L.M., Gujral, J.S., Mulloy, A.L., 2006. Hyperthyroidism: a
secondary cause of isolated systolic hypertension. J. Clin.
Hypertens. 8, 596–599.
Protas, L., Robinson, R.B., 1999. Neuropeptide Y contributes to
innervation-dependent increase in I(Ca, L) via ventricular Y2
receptors. Am. J. Physiol. 277, H940–H946.
Resnick, L.M., Laragh, J.H., 1982. Plasma renin activity in
syndromes of thyroid hormone excess and deficiency. Life Sci.
30, 585–586.
Ribeiro, M.O., Carvalho, S.D., Schultz, J.J., Chiellini, G., Scanlan,
T.S., Bianco, A.C., Brent, G.A., 2001. Thyroid hormone—
sympathetic interaction and adaptive thermogenesis are thyroid
hormone receptor isoform—specific. J. Clin. Invest. 108, 97–105.
Robinson, R.B., 1996. Autonomic receptor–effector coupling during
post-natal development. Cardiovasc. Res. 31, E36–E76.
Rota, M., Boni, A., Urbanek, K., Padin-Iruegas, M.E., Kajstura, T.J.,
Fiore, G., Kubo, H., Sonnenblick, E.H., Musso, E., Houser, S.R.,
Leri, A., Sussman, M.A., Anversa, P., 2005. Nuclear targeting of
Akt enhances ventricular function and myocyte contractility.
Circ. Res. 97, 1332–1341.
Saiki, Y., Konig, A., Waddell, J., Rebeyka, I.M., 1997. Hemodynamic
alteration by fetal surgery accelerates myocyte proliferation in
fetal guinea pig hearts. Surgery 122, 412–419.
Schiros, C.G., Ahmed, M.I., Sanagala, T., Zha, W., Mcgiffin, D.C.,
Bamman, M.M., Gupta, H., Lloyd, S.G., Denney, T.S.J.,
Dell'italia, L.J., 2013. Importance of three-dimensional geomet-
ric analysis in the assessment of the athlete's heart. Am. J.
Cardiol. 111, 1067–1072.
Schwartz, H.L., Lazar, M.A., Oppenheimer, J.H., 1994. Widespread
distribution of immunoreactive thyroid hormone beta 2 receptor
(TR beta 2) in the nuclei of extrapituitary rat tissues. J. Biol.
Chem. 269, 24777–24782.
Sedmera, D., Thompson, R.P., Kolar, F., 2003. Effect of increased
pressure loading on heart growth in neonatal rats. J. Mol. Cell.
Cardiol. 35, 301–309.
Segar, J.L., Volk, K.A., Lipman, M.H., Scholz, T.D., 2013. Thyroid
hormone is required for growth adaptation to pressure load in
the ovine fetal heart. Exp. Physiol. 98, 722–733.
Soonpaa, M.H., Koh, G.Y., Pajak, L., Jing, S., Wang, H., Franklin, M.
T., Kim, K.K., Field, L.J., 1997. Cyclin D1 overexpressionpromotes cardiomyocyte DNA synthesis and multinucleation in
transgenic mice. J. Clin. Invest. 99, 2644–2654.
Spooner, P.H., Morkin, E., Goldman, S., 1999. Thyroid hormone and
thyroid hormone analogues in the treatment of heart failure.
Coron. Artery Dis. 10, 395–399.
Tanaka, H., Shigenobu, K., 1989. Effect of ryanodine on neonatal
and adult rat heart: developmental increase in sarcoplasmic
reticulum function. J. Mol. Cell. Cardiol. 21, 1305–1313.
Tane, S., Kubota, M., Okayama, H., Ikenishi, A., Yoshitome, S.,
Iwamoto, N., Satoh, Y., Kusakabe, A., Ogawa, S., Kanai, A.,
Molkentin, J.D., Nakamura, K., Ohbayashi, T., Takeuchi, T., 2014.
Repression of cyclin D1 expression is necessary for the mainte-
nance of cell cycle exit in adult mammalian cardiomyocytes. J.
Biol. Chem. 289, 18033–18044.
Tata, J.R., 1993. Gene expression during metamorphosis: an ideal
model for post-embryonic development. Bioessays 15, 239–248.
Torres, A., Tucker, D.C., 1993. Effects of thyroid hormones on
cardiac development in oculo. Am. J. Physiol. 264, H244–H251.
Van Rooij, E., Sutherland, L.B., Qi, X., Richardson, J.A., Hill, J.,
Olson, E.N., 2007. Control of stress-dependent cardiac growth
and gene expression by a microRNA. Science 316, 575–579.
Vornanen, M., 1996. Excitation-contraction coupling of the devel-
oping rat heart. Mol. Cell. Biochem. 163–164, 5–11.
Wetzel, G.T., Klitzner, T.S., 1996. Developmental cardiac electro-
physiology recent advances in cellular physiology. Cardiovasc.
Res. 31, E52–E60 (Spec No).
White, P., Burton, K.A., Fowden, A.L., Dauncey, M.J., 2001.
Developmental expression analysis of thyroid hormone receptor
isoforms reveals new insights into their essential functions in
cardiac and skeletal muscles. FASEB J. 15, 1367–1376.
Wibo, M., Bravo, G., Godfraind, T., 1991. Postnatal maturation of
excitation–contraction coupling in rat ventricle in relation to the
subcellular localization and surface density of 1,4-
dihydropyridine and ryanodine receptors. Circ. Res. 68, 662–673.
Wikstrom, L., Johansson, C., Salto, C., Barlow, C., Barros, A.C., Baas,
F., Forrest, D., Thoren, P., Vennstrom, B., 1998. Abnormal heart
rate and body temperature in mice lacking thyroid hormone
receptor alpha 1. EMBO J. 17, 455–461.
Yang, X., Rodriguez, M., Pabon, L., Fischer, K.A., Reinecke, H.,
Regnier, M., Sniadecki, N.J., Ruohola-Baker, H., Murry, C.E.,
2014. Tri-iodo-l-thyronine promotes the maturation of human
cardiomyocytes-derived from induced pluripotent stem cells. J.
Mol. Cell. Cardiol. 72, 296–304.
Zheng, W., Weiss, R.M., Wang, X., Zhou, R., Arlen, A.M., Lei, L.,
Lazartigues, E., Tomanek, R.J., 2004. DITPA stimulates arterio-
lar growth and modifies myocardial postinfarction remodeling.
Am. J. Physiol. Heart Circ. Physiol. 286, H1994–H2000.
Zoeller, R.T., Tan, S.W., Tyl, R.W., 2007. General background on the
hypothalamic–pituitary–thyroid (HPT) axis. Crit. Rev. Toxicol. 37,
11–53.
